A Systematic Review for Targeted Approaches

Paola Pastena,Hiran Perera,Alessandro Martinino,William Kartsonis,Francesco Giovinazzo
DOI: https://doi.org/10.3390/ijms25052559
IF: 5.6
2024-02-23
International Journal of Molecular Sciences
Abstract:Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer, marked by poor outcomes and dismal prognosis. Due to the absence of targetable receptors, chemotherapy still represents the main therapeutic option. Therefore, current research is now focusing on understanding the specific molecular pathways implicated in TNBC, in order to identify novel biomarker signatures and develop targeted therapies able to improve its clinical management. With the aim of identifying novel molecular features characterizing TNBC, elucidating the mechanisms by which these molecular biomarkers are implicated in the tumor development and progression, and assessing the impact on cancerous cells following their inhibition or modulation, we conducted a literature search from the earliest works to December 2023 on PubMed, Scopus, and Web Of Science. A total of 146 studies were selected. The results obtained demonstrated that TNBC is characterized by a heterogeneous molecular profile. Several biomarkers have proven not only to be characteristic of TNBC but also to serve as potential effective therapeutic targets, holding the promise of a new era of personalized treatments able to improve its prognosis. The pre-clinical findings that have emerged from our systematic review set the stage for further investigation in forthcoming clinical trials.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The problem that this paper attempts to solve is the identification of the molecular characteristics of triple - negative breast cancer (TNBC) and its potential treatment targets. Specifically, the paper aims to explore the unique biomarker characteristics in TNBC through a systematic review of existing literature. These biomarkers can not only characterize TNBC but also serve as effective treatment targets to improve the clinical management of TNBC. Due to the lack of targetable receptors in TNBC, chemotherapy remains the main treatment method, but many patients will experience tumor recurrence within the first three years after diagnosis, resulting in a shortened disease - free survival period. Therefore, the current research focuses on understanding the specific molecular pathways involved in TNBC to identify new biomarker characteristics and develop targeted therapies that can improve its clinical management. Through a systematic literature search, from early studies to December 2023, the paper retrieved relevant articles in the PubMed, Scopus, and Web of Science databases and finally screened out 146 studies. The results show that TNBC has a highly heterogeneous molecular profile, and multiple biomarkers not only show specificity in TNBC but may also become potentially effective treatment targets, heralding a new era of personalized treatment. Overall, the goal of this paper is to provide a systematic overview covering the unique molecular characteristics in TNBC, especially those biomarkers that can affect TNBC cell behavior through inhibition or regulation, thereby laying the foundation for further clinical trials.